Financing ·
Radiopharm Theranostics entered into a Securities Purchase Agreement on July 23, 2026, to issue 1,281,646 American…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics entered into a Securities Purchase Agreement on July 23, 2026, to issue 1,281,646 American Depositary Shares (ADSs) at $3.16 per ADS, aiming to raise approximately $4.1 million. The offering includes concurrent unregistered warrants with an exercise price of $3.79 per ADS expiring July 31, 2029. Additionally, the company secured firm commitments for an A$6.7 million Australian private placement and plans a shareholder-approved A$6 million Share Purchase Plan. Proceeds will fund the RAD101 Phase 3 study, RAD 204 dose escalation, and various therapeutic programs including RAD 202, RAD 402, and RV01. The company is a clinical-stage biopharmaceutical company developing oncology radiopharmaceuticals.